猴痘 (Mpox) 治療藥市場:現狀分析與未來預測 (2024年～2032年)

Mpox Treatment Market: Current Analysis and Forecast (2024-2032)

出版日期: 2024年11月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 138 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

猴痘 (Mpox) 治療市場預計在預測期內（2024-2032 年）將以 10.86% 的複合年增長率顯著增長。這主要是由於製藥公司不斷進行研究和開發，並增加了併購活動，以提高他們的能力和佔有率，以增加他們對新進展和技術的了解，從而促進 Mpox 的治療開發。此外，Mpox 盛行率的不斷上升也促進了政府增加支持和資金，以加速治療開發進程。例如，2024年9月，聯合國兒童基金會簽署協議，確保以市場最低價格供應MVA-BN Mpox疫苗，並保證77個低收入和中等收入國家獲得疫苗。該協議旨在滿足對更便宜疫苗的需求。

根據治療類型，市場可分為兩類：預防性和治療性。由於早期幹預，預防性治療類型將在2023年達到最大。預防措施，特別是使用疫苗，對於預防 Mpox 病毒的傳播至關重要。 JYNNEOS 和 Imvanex 是用於預防感染的疫苗，尤其是在流行病期間。此外，各國政府和衛生組織也越來越多地推廣疫苗接種以預防猴痘（Mpox）的爆發，從而促進了預防領域的快速成長。在治療領域，Mpox 治療市場上有三種治療方法：替比馬特、布西多福韋和西多福韋。 Tecobirimat 是市場上使用最廣泛且唯一獲得批准的 Mpox 治療藥物。它是美國食品藥物管理局（FDA）推薦的 Mpox 一線治療藥物。然而，布西多福韋和西多福韋主要用於其他病毒感染，其在 Mpox 治療中的作用尚不清楚，因此在該市場上較少使用。

市場依給藥途徑分為口服藥物和注射藥物。注射劑佔據全球 Mpox 治療市場的最大佔有率。替科維馬和西多福韋等注射藥物比口服藥物起效更快。這對於控制天花等疾病至關重要，天花是一種急性感染，需要患者早期介入。由於這些製劑不通過胃腸道，因此血漿濃度和生物利用度足夠。飲食失調或胃腸道疾病導致的吸收改變可能會進一步降低口服藥物的有效性。然而，臨床醫生和患者對口服療法的日益偏好正在推動這個市場，因為大多數患者更喜歡易於吞嚥的療法。

依銷售管道劃分，市場分為醫院藥局、零售藥局、社區健康中心和線上銷售。在這些細分市場中，由於使用更好的治療方法和疫苗來治療 Mpox，醫院藥局佔據了最大的市場佔有率。醫院藥房允許護理人員將患者護理與其他醫療服務同步，從而促進全面護理。它對於評估患者結果和進行追蹤也很重要，包括與天花相關的併發症。此外，社區健康中心作為分銷管道預計將在改善難以前往醫院的地區的人們獲得 Mpox 治療的機會方面提供巨大潛力。這些中心涵蓋更多患者並產生更好的患者治療效果。

為了更了解 Mpox 治療方案（例如疫苗和療法）的市場介紹，市場將分為北美（美國、加拿大、北美其他地區）、歐洲（德國、法國、英國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度和其他亞太地區）以及世界其他地區。由於水痘在人口中（主要是中國和印度）的盛行率上升，預計亞太地區在 2024 年至 2032 年的預測期內將以顯著的複合年增長率增長。亞太地區的猴痘治療市場將重點關注透過推廣包括疫苗在內的預防措施以及促進研究和開發來製定遏制猴痘的必要措施。例如，2024年8月，巴伐利亞北歐公司宣布，新加坡藥品監管機構健康科學局（HSA）宣布，18歲及以上成年人感染天花或Mpox的風險較高。於預防Mpox 和Mpox 感染。

開展市場上事業的主要企業是下面的那樣的:Bavarian Nordic A/S，SIGA Technologies, Inc.，Tonix Pharmaceuticals Holding Corp.，BioNTech SE.，Emergent BioSolutions Inc.，GeoVax Labs, Inc.，Gilead Sciences, Inc.，KM Biologics Co.。

Bavarian Nordic A/S
- 企業概要
- 主要的財務指標
- SWOT分析
- 產品系列
- 近幾年趨勢
SIGA Technologies, Inc.
Tonix Pharmaceuticals Holding Corp.
BioNTech SE.
Emergent BioSolutions Inc.
GeoVax Labs, Inc.
Gilead Sciences, Inc.
KM Biologics Co., Ltd.
Moderna
Coalition for Epidemic Preparedness Innovations ("CEPI")

第13章縮寫與前提條件

第14章附錄

簡介目錄

Product Code: UMHE213104

Mpox or formerly known as monkeypox is an infectious viral disease which is caused by monkeypox virus, a type of virus of Orthopoxvirus. This disease manifests symptoms as smallpox and causes fever and swollen lymph nodes with flat skin lesions that develop into ulcerated blisters filled with pus, which later crust over. Signs and symptoms usually develop between 1 to 21 days after potential exposure and generally range between two to four weeks. This rash starts in the face and may extend to other parts of the body such as the palms of the hands and soles of the feet. Transmission is through contact with infected persons or animals, contaminated objects, or direct aerosol droplets. In most cases, the signs are relatively mild and go away on their own, but sometimes there could be severe complications in special groups of patients, for example, children and immunocompromised patients. There is a vaccine available, as a preventive measure that is advised for combating this infectious disease.

The Mpox Treatment Market is expected to grow with a significant CAGR of 10.86% during the forecast period (2024-2032). This is mainly due to the continuous research and development by pharmaceutical companies, along with increased mergers and acquisitions activities to boost their capacities and shares to increase their knowledge of new advancements and technologies, which can enhance the development of therapeutics for mpox. Moreover, the increasing incidence of mpox has acted as a catalyst for increased government support and funding to accelerate the therapeutic development process. For instance, in September 2024, UNICEF signed an agreement that secures supply of the MVA-BN mpox vaccine at the lowest market price and ensures access to the vaccine for 77 low- and lower-middle-income countries. This agreement is an effort to meet the demand for more affordable vaccines.

Depending on the treatment type the market is divided into two categories namely prophylactic and therapeutic. Because of early intervention, the prophylactic treatment type segment emerges as the largest in the year 2023. The use of preventive measures and especially the use of vaccines are essential in preventing the spread of mpox virus. JYNNEOS and Imvanex are some vaccines that are used to prevent infections, especially during the period of the outbreak. Besides, governments and health organizations are inclining more towards vaccination drives in order to prevent mpox outbreaks hence contributing to a high growth rate of the prophylactic segment. In the therapeutic segment, there are three therapeutics available in the mpox treatment market, these are tecovirimat, brincidofovir, and cidofovir. The tecovirimat therapeutic is the most widely used and only approved therapeutics in the mpox treatment market. It is the first-line therapeutic treatment recommended by the U.S. Food and Drug Administration (FDA) for Mpox. However, brincidofovir and cidofovir are used in other viral infections primarily and their role in mpox treatment is not quite clear therefore they are not widely used in this market.

Based on the route of administration, the market is segmented into oral and injectable segments. The injectable segment holds the maximum share of the global Mpox treatment Market. Injectable medications, such as tecovirimat and cidofovir, provide faster therapeutic effects than oral formulations. This is very important in controlling diseases like mpox that present acute infection and call for early action on the patients. These formulations do not pass through the gastrointestinal feed, hence giving full bioavailability as well as plasma concentration levels. The efficacy of oral medications may be further compromised by changes in absorption caused by food interference or gastrointestinal illnesses. However, the growing preference by clinicians and patients for oral therapies boosts this market as the majority of the patients prefer easy-to-swallow therapies.

According to the distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, Community Health Centers, and online. In these segments, the hospital pharmacy has taken the largest market share owing to the usage of better therapeutics and vaccines available for mpox treatment. Hospital pharmacies promote integrated care by enabling caregivers to synchronize patient care with other health services. It is also important when assessing patients' outcomes and performing follow-ups that may include complications that are related to mpox. Additionally, the Community Health Centers as a distribution channel is expected to offer great potential in improving Mpox treatment access to the people living in areas where hospitals are not accessible. These centers produce better patient outcomes by reaching patients in large numbers.

For a better understanding of the market adoption of mpox treatment options such as vaccines and therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The Asia-Pacific region is anticipated to grow with a considerable CAGR in the forecast period of 2024-2032 due to the rising incidence of mpox in the population, predominantly in China and India. It is to be emphasized on creating the necessary measures for containing mpox through the promotion of prevention measures including vaccines and with promoting research and development in mpox treatment market within the Asia-Pacific region. For instance, on August 2024, Bavarian Nordic A/S announced that Singapore's medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS(R) (MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.

Some of the major players operating in the market include Bavarian Nordic A/S, SIGA Technologies, Inc., Tonix Pharmaceuticals Holding Corp., BioNTech SE., Emergent BioSolutions Inc., GeoVax Labs, Inc., Gilead Sciences, Inc., KM Biologics Co., Ltd., Moderna, Coalition for Epidemic Preparedness Innovations ("CEPI").

1.MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Mpox Treatment Market
2.2. Research Methodology of the Mpox Treatment Market
2.3. Respondent Profile

3.EXECUTIVE SUMMARY

3.1. Industry Synopsis
3.2. Segmental Outlook
- 3.2.1. Market Growth Intensity
3.3. Regional Outlook

4.MARKET DYNAMICS

4.1. Drivers
4.2. Opportunity
4.3. Restraints
4.4. Trends
4.5. PESTEL Analysis
4.6. Demand Side Analysis
4.7. Supply Side Analysis
- 4.7.1. Partnership & Collaborations
- 4.7.2. Investment Scenario

5.GLOBAL MPOX TREATMENT MARKET REVENUE (USD MN), 2022-2032F

6.MARKET INSIGHTS BY TREATMENT TYPE

6.1. Prophylactic
6.2. Therapeutic

7.MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

7.1. Oral
7.2. Injectable

8.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

8.1. Hospital Pharmacies
8.2. Community Health Centres
8.3. Retail Pharmacies
8.4. Online

9.MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World

10.VALUE CHAIN ANALYSIS

11.COMPETITIVE LANDSCAPE

11.1. Competition Dashboard
11.2. Competitor Market Positioning Analysis
11.3. Porter Five Forces Analysis

12.COMPANY PROFILES

12.1. Bavarian Nordic A/S
- 12.1.1. Company Overview
- 12.1.2. Key Financials
- 12.1.3. SWOT Analysis
- 12.1.4. Product Portfolio
- 12.1.5. Recent Developments
12.2. SIGA Technologies, Inc.
12.3. Tonix Pharmaceuticals Holding Corp.
12.4. BioNTech SE.
12.5. Emergent BioSolutions Inc.
12.6. GeoVax Labs, Inc.
12.7. Gilead Sciences, Inc.
12.8. KM Biologics Co., Ltd.
12.9. Moderna
12.10. Coalition for Epidemic Preparedness Innovations ("CEPI")